Optic neuropathy induced by ethambutol: A rare case from Nepal

Shah, Sangam; Adhikari, Yagya Raj; Paudel, Sushil; Sitaula, Sanjeeta; Koirala, Bipin; Aryal, Suraj; Pande, Yubraj; Karki, Ruchi

doi:10.1016/j.amsu.2022.103637

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sangam shah et.al Ethambutol is a medicine used to treat tuberculosis, but it also has adverse effects like vision problems, which can result in optic neuropathy. It is uncommon (1% frequency) and often appears 4-12 months after starting treatment.The most prevalent ocular symptoms of ethambutol-induced optic neuropathy include central vision loss, centrocaecal scotoma, and acquired colour vision defect [9].…”

Section: Fig 1 Optical Coherence Tomographymentioning

confidence: 99%

A Rare Incidence of Ethambutol Induced Toxic Optic Neuropathy

Mousigan¹,

Nissi²,

Sreenivasan³

2023

IJMPCR

View full text Add to dashboard Cite

Ethambutol induces toxic optic neuropathy (EON), which most typically presents as bilateral symmetrical loss of vision and, due to a lack of early detection and adequate treatment, often causes serious irreversible visual impairment. EON is time and dose dependent. In this case report, we will discuss a 59-year-old female patient who came in with complaints of visual impairment, inclusive of a colour vision defect (dyschromatopsia) and blurred vision (scotoma). Her past medication history includes use of first-line anti-tubercular therapy (ATT) with four drugs: Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide. Pyrazinamide was taken for two months, and other medications (Rifampicin, Isoniazid, and Ethambutol) were taken for a period of seven months. From this case report, we will get a clear picture necessitating continuous monitoring for ocular toxicity.

show abstract

Section: Fig 1 Optical Coherence Tomographymentioning

confidence: 99%

A Rare Incidence of Ethambutol Induced Toxic Optic Neuropathy

Mousigan¹,

Nissi²,

Sreenivasan³

2023

IJMPCR

View full text Add to dashboard Cite

show abstract

“…First-line treatment with isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) remains the mainstay of treatment of TB, which has the adverse effects like hepatotoxicity, peripheral neuropathy, optic neuritis, and so on. [2][3][4] Cutaneous Adverse Drug reactions (CADRs) are the wellknown side effects of first-line antitubercular drugs; mild transient reactions (such as mild pruritus) do not result in treatment interruption. However, in severe cases, they can lead to life-threatening toxic epidermal necrolysis (TEN), which may necessitate to discontinuation of treatment and further complicate the treatment process.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cutaneous drug reaction secondary to antitubercular regimen: A case report from Nepal

Bhattarai,

Yadav,

Sapkota

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Cutaneous adverse drug reactions are known side effects of first-line antitubercular therapy, which ranges from mild pruritus to life-threatening toxic epidermal necrolysis. Severe cutaneous adverse drug reactions can lead to antitubercular therapy discontinuation and further complicates tuberculosis treatment. Here we present the case of a 49-year-old obese male who developed a generalized maculopapular rash within 24 hours of initiation of therapy followed by bullae over palms in 3 days. Antitubercular therapy was immediately discontinued, and he was managed with antihistamines, intravenous fluid, and electrolyte supplementation. He was discharged on antihistamines, a short course of systemic steroids, moxifloxacin, and bedaquiline (second-line antitubercular therapy (ATT)). Proper guidelines about rechallenge therapy will enormously aid in managing cutaneous adverse drug reactions, and efficient treatment of tuberculosis in these patients, and ceasing its progression to multisystemic complications. This article aims to discuss the presentation and management of cutaneous adverse drug reactions in the setting of Nepal.

show abstract

Ethambutol

2022

Reactions Weekly

View full text Add to dashboard Cite

Optic neuropathy induced by ethambutol: A rare case from Nepal

Cited by 4 publications

References 9 publications

A Rare Incidence of Ethambutol Induced Toxic Optic Neuropathy

A Rare Incidence of Ethambutol Induced Toxic Optic Neuropathy

Cutaneous drug reaction secondary to antitubercular regimen: A case report from Nepal

Ethambutol

Contact Info

Product

Resources

About